Cargando…
Multiplatform profiling of pancreatic neuroendocrine tumors: Correlative analyses of clinicopathologic factors and identification of co-occurring pathogenic alterations
BACKGROUND: Multi-omic profiling of pancreatic neuroendocrine tumors (PanNETs) was performed to correlate genomic, proteomic, and molecular pathway alterations with clinicopathologic factors and identify novel co-occurring pathogenic alterations of potential clinical relevance to PanNET management....
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6817448/ https://www.ncbi.nlm.nih.gov/pubmed/31692857 http://dx.doi.org/10.18632/oncotarget.27265 |
_version_ | 1783463422920228864 |
---|---|
author | Gong, Jun Blais, Edik M. Bender, Joseph R. Guan, Michelle Placencio-Hickok, Veronica Petricoin, Emanuel F. Pishvaian, Michael J. Gregory, Gary Tuli, Richard Hendifar, Andrew E. |
author_facet | Gong, Jun Blais, Edik M. Bender, Joseph R. Guan, Michelle Placencio-Hickok, Veronica Petricoin, Emanuel F. Pishvaian, Michael J. Gregory, Gary Tuli, Richard Hendifar, Andrew E. |
author_sort | Gong, Jun |
collection | PubMed |
description | BACKGROUND: Multi-omic profiling of pancreatic neuroendocrine tumors (PanNETs) was performed to correlate genomic, proteomic, and molecular pathway alterations with clinicopathologic factors and identify novel co-occurring pathogenic alterations of potential clinical relevance to PanNET management. METHODS: PanNETs referred to Perthera, Inc. having undergone molecular profiling for precision matched therapeutic purposes were screened. Correlative analyses were performed using Fisher’s exact test across individual pathogenic alterations or altered molecular pathways and clinicopathologic variables. Associations were visualized by hierarchical clustering. Prognostic associations with overall survival (OS) were identified using Cox regression for pathogenic alterations and pathway-level alterations. Hazard ratios (HR) and odds ratios (OR) were reported with 95% confidence intervals (CI). RESULTS: From 12/2014–1/2019, 46 patients with predominantly locally advanced and metastatic PanNETs were included. MEN1 alterations by next-generation sequencing (NGS) were less associated with having high-grade PanNETs and metastatic disease at diagnosis (p ≤ 0.05). Genomic alterations associated with increased replicative stress (primarily driven by RB1 and TP53) correlated with higher grade (OR 6.87 [95% CI: 1.57-35.18], p = 0.0043) and worse OS (HR 13.62 [95% CI: 1.51-122.5], p = 0.0198). Other significant associations included: ERCC1 protein expression with DAXX or MEN1 alterations (NGS), PTEN (NGS) with ARID1A or TP53 alterations (NGS), and history of diabetes coincided with cell cycle pathway alterations but was mutually exclusive with replicative stress pathway alterations. CONCLUSIONS: We identified several molecular signatures of potential clinical significance for therapeutic targeting and prognostication in PanNETs warranting prospective validation. Our findings are hypothesis generating and can inform larger molecular profiling efforts in PanNETs. |
format | Online Article Text |
id | pubmed-6817448 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-68174482019-11-05 Multiplatform profiling of pancreatic neuroendocrine tumors: Correlative analyses of clinicopathologic factors and identification of co-occurring pathogenic alterations Gong, Jun Blais, Edik M. Bender, Joseph R. Guan, Michelle Placencio-Hickok, Veronica Petricoin, Emanuel F. Pishvaian, Michael J. Gregory, Gary Tuli, Richard Hendifar, Andrew E. Oncotarget Research Paper BACKGROUND: Multi-omic profiling of pancreatic neuroendocrine tumors (PanNETs) was performed to correlate genomic, proteomic, and molecular pathway alterations with clinicopathologic factors and identify novel co-occurring pathogenic alterations of potential clinical relevance to PanNET management. METHODS: PanNETs referred to Perthera, Inc. having undergone molecular profiling for precision matched therapeutic purposes were screened. Correlative analyses were performed using Fisher’s exact test across individual pathogenic alterations or altered molecular pathways and clinicopathologic variables. Associations were visualized by hierarchical clustering. Prognostic associations with overall survival (OS) were identified using Cox regression for pathogenic alterations and pathway-level alterations. Hazard ratios (HR) and odds ratios (OR) were reported with 95% confidence intervals (CI). RESULTS: From 12/2014–1/2019, 46 patients with predominantly locally advanced and metastatic PanNETs were included. MEN1 alterations by next-generation sequencing (NGS) were less associated with having high-grade PanNETs and metastatic disease at diagnosis (p ≤ 0.05). Genomic alterations associated with increased replicative stress (primarily driven by RB1 and TP53) correlated with higher grade (OR 6.87 [95% CI: 1.57-35.18], p = 0.0043) and worse OS (HR 13.62 [95% CI: 1.51-122.5], p = 0.0198). Other significant associations included: ERCC1 protein expression with DAXX or MEN1 alterations (NGS), PTEN (NGS) with ARID1A or TP53 alterations (NGS), and history of diabetes coincided with cell cycle pathway alterations but was mutually exclusive with replicative stress pathway alterations. CONCLUSIONS: We identified several molecular signatures of potential clinical significance for therapeutic targeting and prognostication in PanNETs warranting prospective validation. Our findings are hypothesis generating and can inform larger molecular profiling efforts in PanNETs. Impact Journals LLC 2019-10-22 /pmc/articles/PMC6817448/ /pubmed/31692857 http://dx.doi.org/10.18632/oncotarget.27265 Text en http://creativecommons.org/licenses/by/3.0/ Copyright: Gong et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Gong, Jun Blais, Edik M. Bender, Joseph R. Guan, Michelle Placencio-Hickok, Veronica Petricoin, Emanuel F. Pishvaian, Michael J. Gregory, Gary Tuli, Richard Hendifar, Andrew E. Multiplatform profiling of pancreatic neuroendocrine tumors: Correlative analyses of clinicopathologic factors and identification of co-occurring pathogenic alterations |
title | Multiplatform profiling of pancreatic neuroendocrine tumors: Correlative analyses of clinicopathologic factors and identification of co-occurring pathogenic alterations |
title_full | Multiplatform profiling of pancreatic neuroendocrine tumors: Correlative analyses of clinicopathologic factors and identification of co-occurring pathogenic alterations |
title_fullStr | Multiplatform profiling of pancreatic neuroendocrine tumors: Correlative analyses of clinicopathologic factors and identification of co-occurring pathogenic alterations |
title_full_unstemmed | Multiplatform profiling of pancreatic neuroendocrine tumors: Correlative analyses of clinicopathologic factors and identification of co-occurring pathogenic alterations |
title_short | Multiplatform profiling of pancreatic neuroendocrine tumors: Correlative analyses of clinicopathologic factors and identification of co-occurring pathogenic alterations |
title_sort | multiplatform profiling of pancreatic neuroendocrine tumors: correlative analyses of clinicopathologic factors and identification of co-occurring pathogenic alterations |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6817448/ https://www.ncbi.nlm.nih.gov/pubmed/31692857 http://dx.doi.org/10.18632/oncotarget.27265 |
work_keys_str_mv | AT gongjun multiplatformprofilingofpancreaticneuroendocrinetumorscorrelativeanalysesofclinicopathologicfactorsandidentificationofcooccurringpathogenicalterations AT blaisedikm multiplatformprofilingofpancreaticneuroendocrinetumorscorrelativeanalysesofclinicopathologicfactorsandidentificationofcooccurringpathogenicalterations AT benderjosephr multiplatformprofilingofpancreaticneuroendocrinetumorscorrelativeanalysesofclinicopathologicfactorsandidentificationofcooccurringpathogenicalterations AT guanmichelle multiplatformprofilingofpancreaticneuroendocrinetumorscorrelativeanalysesofclinicopathologicfactorsandidentificationofcooccurringpathogenicalterations AT placenciohickokveronica multiplatformprofilingofpancreaticneuroendocrinetumorscorrelativeanalysesofclinicopathologicfactorsandidentificationofcooccurringpathogenicalterations AT petricoinemanuelf multiplatformprofilingofpancreaticneuroendocrinetumorscorrelativeanalysesofclinicopathologicfactorsandidentificationofcooccurringpathogenicalterations AT pishvaianmichaelj multiplatformprofilingofpancreaticneuroendocrinetumorscorrelativeanalysesofclinicopathologicfactorsandidentificationofcooccurringpathogenicalterations AT gregorygary multiplatformprofilingofpancreaticneuroendocrinetumorscorrelativeanalysesofclinicopathologicfactorsandidentificationofcooccurringpathogenicalterations AT tulirichard multiplatformprofilingofpancreaticneuroendocrinetumorscorrelativeanalysesofclinicopathologicfactorsandidentificationofcooccurringpathogenicalterations AT hendifarandrewe multiplatformprofilingofpancreaticneuroendocrinetumorscorrelativeanalysesofclinicopathologicfactorsandidentificationofcooccurringpathogenicalterations |